Sonia Pernas, Head of Breast Cancer Unit at Catalan Institute of Oncology, shared on LinkedIn about a recent paper she co-authored with colleagues:
“I’m delighted to share the publication of the SUMIT-BC phase II randomized trial in Nature Communications, where I had the privilege of serving as first author!
This is the first randomized trial evaluating the oral CDK7 inhibitor samuraciclib plus fulvestrant in patients with HR+/HER2− advanced breast cancer following progression on CDK4/6 inhibitors.
Key findings
- Improved clinical benefit with samuraciclib plus fulvestrant compared with fulvestrant alone.
- Particularly encouraging results in patients with TP53 wild-type tumors, with a median progression-free survival of 14.5 vs. 6.8 months (samuraciclib 360 mg + fulvestrant vs. fulvestrant alone).
- These findings support further investigation of CDK7 inhibition as a potential treatment strategy in this setting.
Although these results need confirmation in larger trials, they represent a promising step toward more personalized treatment approaches.
I’m especially proud of the contribution of our team at Institut Català d’Oncologia (ICO), Bellvitge Biomedical Research Institute – IDIBELL which was the top-recruiting site in this international study involving 26 centers across five countries.
A huge thank you to all the patients and their families, investigators, the entire clinical research team and Carrick Therapeutics who made this study possible!”
Title: A randomized controlled trial of CDK7 inhibitor samuraciclib plus fulvestrant in advanced HR+/HER2− breast cancer
Authors: Sonia Pernas, Cengiz Karacin, Carlos Gonzalez-Nuñez, Sercan Aksoy, Meritxell Bellet Ezquerra, Nuri Karadurmus, Ozan Yazici, Maysa Abu-Khalaf, Begoña Bermejo de lasHeras, Marta Gonzalez Cordero, Mahmut Gumus, Carmen Hinojo, Rebeca Lozano Mejorada, Emmanuel de la Mora Jimenez, Carlos Zuloaga Fernandez del Valle, Cagatay Arslan, Shweta Kurian, María Martínez García, Daniel Motola-Kuba, Javier Pascual, Timothy Pluard, Gyongyver Szentmartoni, Glen Clack, Ash Bahl, Stuart McIntosh, Raoul Charles Coombes.
Read the full article.
This also can be interesting:
How Systemic Therapy Is Reshaping Breast Cancer Care in 2026
